CClinicalTrials.gg
RecruitingNCT06659367Updated Oct 26, 2024

Dedinje FFR/QFR Registry

An observational study in Coronary Artery Disease (CAD) and Fractional Flow Reserve, sponsored by Institute for Cardiovascular Diseases Dedinje. Recruiting at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Institute for Cardiovascular Diseases Dedinje · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Study summary

Quantitative Flow Ratio (QFR) has shown good diagnostic performance against Fractional Flow Reserve (FFR) in several meta-analyses, comparable or even superior to nonhyperemic pressure ratios. However, the reproducibility of QFR is modest and there is high inter- and intra-observer variability even when fairly experienced but non-core lab operators (at least 150 QFR procedure experience) are performing the analysis. Although smaller studies have demonstrated that non-core analysis and even paramedical user analysis can have good correlation with FFR, the concern about the diagnostic performance of QFR in real-world clinical practice by inexperienced users remains.

The primary objective of "Dedinje FFR/QFR Registry" is to determine the feasibility and diagnostic performance of QFR analysis by vendor-certified inexperienced medical users in a real-world setting using FFR as the gold standard. All patients >18 years old who present to the Institute for Cardiovascular Diseases "Dedinje" and undergo a planned or ad hoc FFR procedure will be asked to participate in the registry. FFR procedure is performed according to the standardized institutional protocol. QFR analysis will be subsequently performed offline according to a standard operating procedure.

02

Conditions studied

  • Coronary Artery Disease (CAD)
  • Fractional Flow Reserve

Keywords

  • coronary artery disease
  • fractional flow reserve
  • quantitative flow ratio
  • FFR
  • QFR
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Institute for Cardiovascular Diseases Dedinje is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients >18 years old who present to the Institute for Cardiovascular Diseases "Dedinje" and undergo a planned or ad hoc FFR procedure will be asked to participate in the registry.

Inclusion criteria

  • >18 years old
  • Had a clinically indicated FFR procedure performed (either as a planned procedure or ad hoc)

Exclusion criteria

Exclusion Criteria:

  • Declines to participate in the registry and provide informed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Correlation between Quantitative Flow Ratio (QFR) and Fractional Flow Reserve (FFR)

    correlation coefficient (r) between Quantitative Flow Ratio (QFR) and Fractional Flow Reserve (FFR)

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  2. Sensitivity of Quantitative Flow Ratio (QFR)

    Sensitivity of Quantitative Flow Ratio (QFR) against Fractional Flow Reserve (FFR) as the gold standard

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  3. Specificity of Quantitative Flow Ratio (QFR)

    Specificity of Quantitative Flow Ratio (QFR) against Fractional Flow Reserve (FFR) as the gold standard

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  4. Positive predictive value of Quantitative Flow Ratio (QFR)

    Positive predictive value of Quantitative Flow Ratio (QFR) against Fractional Flow Reserve (FFR) as the gold standard

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  5. Negative predictive value of Quantitative Flow Ratio (QFR)

    Negative predictive value of Quantitative Flow Ratio (QFR) against Fractional Flow Reserve (FFR) as the gold standard

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  6. Diagnostic gray zone

    Quantitative Flow Ratio (QFR) limits for achieving 95% sensitivity and specificity in comparison to Fractional Flow Reserve (FFR)

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  7. Diagnostic accuracy of Quantitative Flow Ratio (QFR) against Fractional Flow Reserve (FFR)

    Area under the curve (using cutoff values of \<=0.80 for both methods)

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

Secondary outcomes

  1. Diagnostic performance of nonhyperemic pressure ratios and 3-dimensional Quantitative Coronary Angiography (3D-QCA) against Fractional Flow Reserve (FFR) as the gold standard

    Sensitivity, specificity, positive predictive value and negative predictive value of nonhyperemic pressure ratios and 3-dimensional Quantitative Coronary Angiography (3D-QCA) against Fractional Flow Reserve (FFR)

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  2. Diagnostic accuracy of nonhyperemic pressure ratios and 3-dimensional Quantitative Coronary Angiography (3D-QCA) against Fractional Flow Reserve (FFR) as the gold standard

    Area under the curve (using cutoff values of \<=0.89 for nonhyperemic pressure ratios and \>=50% diameter stenosis for 3-dimensional Quantitative Coronary Angiography (3D-QCA)) against Fractional Flow Reserve (FFR, cutoff value \<=0.80)

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  3. Inter-observer variability

    Coefficient of variation for repeated Quantitative Flow Ratio (QFR) computation between users, standard deviation for repeated Quantitative Flow Ratio (QFR) measurements between users, binary diagnostic classification agreement between users

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  4. Intra-observer variability

    Coefficient of variation for repeated Quantitative Flow Ratio (QFR) computation within users, standard deviation for repeated Quantitative Flow Ratio (QFR) measurements within users, binary diagnostic classification agreement within users

    Time frame: at the time of Quantitative Flow Ratio (QFR) analysis completion (up to 1 year)

  5. All-cause death

    All-cause death

    Time frame: at 6 months, 1 year and annually for 5 years

  6. Myocardial infarction

    Myocardial infarction

    Time frame: at 6 months, 1 year and annually for 5 years

  7. Vessel-oriented composite outcome

    Cardiac death, vessel-related myocardial infarction and ischemia-driven target vessel revascularization

    Time frame: at 6 months, 1 year and annually for 5 years

  8. Change in Seattle Angina Questionnaire-7 Items Score (SAQ-7) at 6 months

    Change in Seattle Angina Questionnaire-7 Items Score (SAQ-7) at 6 months from the time of the Fractional Flow Reserve (FFR) procedure. (scale 0-100, 100 = full health, 0 = worst health)

    Time frame: 6 months

  9. Change in EuroQol-5 Dimensions- 5 Levels (EQ-5D-5L) Score

    Change in EuroQol-5 Dimensions- 5 Levels (EQ-5D-5L) Score at 6 months from the time of the Fractional Flow Reserve (FFR) procedure (scale 5-25, 5= no problems in any dimension, 25= extreme problems on all dimensions; visual analogue scale 0-100, 0= worst health possible, 100= best health possible)

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Institute for Cardiovascular Diseases "Dedinje"
    Belgrade, 11040, Serbia
    • Natalija Odanovic · Contact · natalija.odanovic@gmail.com · +381654732220
    • Natalija Odanovic, MD · Principal investigator
    • Milan Dobric, MD, PhD · Sub investigator
    • Ivan Ilic, MD, PhD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD contains sensitive identifying patient information that patients are told will not be shared with anyone outside of the primary team of researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06659367
Lead sponsor
Institute for Cardiovascular Diseases Dedinje
Responsible party
Natalija Odanovic (Principal Investigator, Institute for Cardiovascular Diseases Dedinje) — Principal investigator
First posted
Oct 26, 2024
Start date
Oct 2, 2024
Primary completion
Oct 2, 2029 (estimated)
Completion
Oct 2, 2034 (estimated)
Last update
Oct 26, 2024

Study contacts

Natalija Odanovic, MD
Contact
natalija.odanovic@gmail.com
+381654732220

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion